Intracavitary cisplatin chemotherapy for mesothelioma

Pfeifle, C.E.; Howell, S.B.; Markman, M.; Pfeifle, C.E; Howell, S.B; Markman, M

Home

>

Node

>

Subnode

Intracavitary cisplatin chemotherapy for mesothelioma

Pfeifle, C.E.; Howell, S.B.; Markman, M.

Cancer Treatment Reports 69(2): 205-207

1985

ISSN/ISBN: 0361-5960

PMID: 4038626

Document Number: 242489

A feasibility study of intracavitary cisplatin was conducted in eight patients with mesothelioma. Cisplatin, 90 mg/m2, was instilled weekly for 3 weeks, followed by a 3-week rest; thiosulfate was given iv to reduce nephrotoxicity. In 50 courses there was no chemical serositis; the major toxic effect was myelosuppression. One patient with measurable disease had a complete response; three others had objective responses.